TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34544853
Drug: Task-specific motor
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-specific motor therapy (20 extra hours) starting at 2 to 3 months after stroke (subacute)
Study: 34544853
Drug: Task-specific motor
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-specific motor therapy (20 extra hours) starting at ≥6 months after stroke (chronic)
Study: 33431304
Drug: Micro-dosed carbohydrate-electrolyte
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-dosed carbohydrate-electrolyte solution
Study: 32350650
Drug: Consideration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consideration of prismatic side-effects of spectacle lenses and eye ball length in dosage planning (intervention group)
Study: 32350650
Drug: No consideration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No consideration of prismatic side-effects of spectacle lenses and eye ball length in dosage planning (control group)
Study: 35172056
Drug: EDP-938 600
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-938 600 mg once daily
Study: 35172056
Drug: EDP-938 300
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-938 300 mg twice daily after a 500 mg loading dose
Study: 34098518
Drug: Daridorexant (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daridorexant (50 mg)
Study: 34098518
Drug: Daridorexant (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daridorexant (50 mg) + Citalopram (20 mg at steady state)
Study: 35898486
Drug: Daily finger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily finger gymnastics; exercise 2-3 times per day, ibuprofen sustained-release capsules if excessive pain occurs.
Study: 34416778
Drug: Ibuprofen enema
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen enema
Study: 34416778
Drug: Both ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both ibuprofen enema and suppository
Study: 33375952
Drug: Buprenorphine (BUP)
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine (BUP) 0.02 mg/kg IM
Study: 33375952
Drug: Sustained-release buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release buprenorphine (BSR) 0.2 mg/kg SC
Study: 35747181
Drug: 2-dose measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose measles vaccination (MV) with no C-OPV
Study: 35747181
Drug: 2-dose measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose measles vaccination (MV) at 4 months with maternal measles antibodies (MatAb)
Study: 32966722
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg zinc sulfate for 14 days
Study: 32966722
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zinc sulfate for 14 days
Study: 32966722
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg zinc sulfate for 14 days
Study: 34856936
Drug: Avelumab combined
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab combined with dose-dense methotrexate-vinblastine-doxorubicin-cisplatin
Study: 35284778
Drug: Emicizumab 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emicizumab 1.5 mg/kg once weekly (arm A)
Study: 35284778
Drug: Emicizumab 6
Normalized name: EMICIZUMAB 60 mg in 0.4 mL SUBCUTANEOUS INJECTION, SOLUTION [Hemlibra]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emicizumab 6 mg/kg every 4 weeks (arm B)
Study: 34482179
Drug: Tomuzotuximab (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomuzotuximab (initial dose 990 mg then 720 mg) weekly with cisplatin 100 mg/m2 and fluorouracil (5-FU; 1000 mg/m2/day, days 1-4) every 3 weeks
Study: 34482179
Drug: Cetuximab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (400 mg/m2 subsequent 250 mg/m2) weekly with the same chemotherapeutic backbone
Study: 35040416
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (32 cases)
Study: 34047716
Drug: PEG with
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG with electrolyte (50 mL/kg) and oral bisacodyl (PEG+B group)
Study: 34047716
Drug: PEG with
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG with electrolyte (70 mL/kg) and glycerol enema (PEG+G group)
Study: 34047716
Drug: PEG+G group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG+G group
Study: 39641404
Drug: Daridorexant 25
Normalized name: daridorexant 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daridorexant 25 mg
Study: 35960814
Drug: Combined Er:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Er:YAG laser and Nd:YAG laser treatment
Study: 34366004
Drug: Complex interprofessional
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex interprofessional intervention including drug review by pharmacists, educational sessions for general practitioners and nurses, a drug safety toolbox, and change management seminars for 23 nursing homes with 452 residents.
Study: 33545941
Drug: Herb-partitioned moxibustion
Normalized name: Purslane Herb
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herb-partitioned moxibustion plus lifestyle modification treatment
Study: 34140144
Drug: Conventional-dose SRT
Normalized name: SRT-1720
DrugBank: SRT-1720 (DB17057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose SRT (64 Gy)
Study: 34140144
Drug: Dose-intensified SRT
Normalized name: SRT-1720
DrugBank: SRT-1720 (DB17057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-intensified SRT (70 Gy)
Study: 32783554
Drug: Standard-Dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-Dose CT (SDCT)
Study: 34229149
Drug: amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxicillin
Study: 35363318
Drug: Ruxolitinib 10
Normalized name: ruxolitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 10 mg twice daily (n = 165)
Study: 35363318
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available therapy (BAT) (n = 164)
Study: 36652465
Drug: SGLT-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT-2 inhibitors
Study: 35951014
Drug: 0.5% EGCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% EGCG (10 mg/kg daily dose)
Study: 35233908
Drug: ertugliflozin 15
Normalized name: ertugliflozin 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ertugliflozin 15 mg
Study: 616863419
Drug: Gymnema sylvestre
Normalized name: GYMNEMA SYLVESTRE LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gymnema sylvestre (GS) treatment
Study: 36131291
Drug: Metformin (initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (initiated at 500mg/day, titrated to a maximum of 2500mg over 10 days)
Study: 32036242
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of CBD (Epidiolex® or Epidyolex®)
Study: 36336841
Drug: Sintilimab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab (200 mg every 3 weeks)
Study: 34215316
Drug: Bazedoxifene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene (20 mg/day) with elemental calcium 1200 mg and vitamin D 800 IU daily
Study: 34215316
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (calcium 1200 mg and vitamin D 800 IU only)
Study: 34939373
Drug: Anlotinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib (12 mg/day)
Study: 32641163
Drug: Hydroxychloroquine 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 800 mg orally in two doses followed by 400 mg daily in two doses and azithromycin 500 mg orally in one dose followed by 250 mg in one dose for a total of 5 days (HC-A group)
Study: 39602203
Drug: Treatment-as-usual control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual control group
Study: 38650969
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers (BB)
Study: 33879151
Drug: Unauthorized trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unauthorized trials with mismatched therapeutic indications, posology, or administration method
Study: 33879151
Drug: Unauthorized trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unauthorized trial including a drug therapy intervention with an unapproved active substance
Study: 32458778
Drug: Recent antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent antibiotic use
Study: 32151878
Drug: NC Gut
Normalized name: codeine phosphate / pseudoephedrine hydrochloride / triprolidine hydrochloride Oral Solution [Poly Hist NC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NC Gut Relief Formula (5 g/d for 4 weeks, then 10 g/d for 4 weeks)
Study: 35666250
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) program, 10 sessions
Study: 32546726
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard chemotherapy)
Study: 33403699
Drug: Oral Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Vancomycin
Study: 35667569
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (SM)
Study: 34449946
Drug: Vitrification treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitrification treatment + 5?M of Retinol
Study: 35851518
Drug: Single session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single session of Botulinum toxin A injection
Study: 35851518
Drug: Multiple sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple sessions of multivitamins mesotherapy injection
Study: 36443174
Drug: Etanercept (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (50 mg then 25 mg x 5 doses)
Study: 36443174
Drug: Alpha-1 antitrypsin
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-1 antitrypsin (A1AT) (90 mg/kg x 6 doses)
Study: 33819452
Drug: High-protein, high-calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein, high-calorie oral nutritional supplements (ONS), 2 bottles daily for 3 months
Study: 33685706
Drug: Sedated: lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedated: lidocaine cornual nerve block, 0.5 mg/kg meloxicam (subcutaneously), and 0.2 mg/kg xylazine (intramuscularly)
Study: 35788146
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no laser treatment)
Study: 32195639
Drug: Laser group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser group (445-nm diode laser treatment)
Study: 34302745
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg daily orally)
Study: 32791501
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) and Well-Being Therapy (WBT)
Study: 34116270
Drug: Chemotherapy-induced ovarian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-induced ovarian failure (CIOF) after anthracycline/taxane-based chemotherapy
Study: 34116270
Drug: Regain of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regain of premenopausal hormone levels after chemotherapy
Study: 32147076
Drug: Green coffee
Normalized name: Green coffee bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green coffee extract (GCE) 400 mg daily for 8 weeks
Study: 39039548
Drug: Propofol-based total
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-based total intravenous anesthesia (TIVA)
Study: 32990215
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment and Placebo
Study: 35334388
Drug: Vasopressin administration
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin administration
Study: 34959949
Drug: Carrot-derived rhamnogalacturonan-I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrot-derived rhamnogalacturonan-I (cRG-I) at 0.3 g/day
Study: 36453726
Drug: Bone channeling
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone channeling augmentation
Study: 37783947
Drug: MSC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSC therapy
Study: 32127275
Drug: High heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High heparin dose (600 IU/kg)
Study: 32127275
Drug: Low heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low heparin dose (300 IU/kg)
Study: 34511049
Drug: Probiotic (Lab4)
Normalized name: Rezyst Probiotic
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (Lab4) plus 50 mg vitamin C
Study: 33213530
Drug: Favipiravir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Favipiravir plus standard treatment for COVID‐19 (loading dose of 3600mg on day 1, followed by 800mg 12 hours apart for 9 days)
Study: 33213530
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for COVID‐19 (at the discretion of the treating clinician)
Study: 32900856
Drug: NP-administered POCUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP-administered POCUS
Study: 35241538
Drug: Cisplatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (40 mg/m2)
Study: 32725411
Drug: Paclitaxel-coated drug-eluting
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-coated drug-eluting stents (DES)
Study: 35022480
Drug: Lymphatic Contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphatic Contrast Enhanced Ultrasound (LCEUS) with Sonazoid injection
Study: 36362489
Drug: Doll Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doll Therapy Intervention (DTI)
Study: 32173165
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard preparation)
Study: 34543161
Drug: Valsartan 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 0.25 mg/kg/day (CKD subgroup)
Study: 34543161
Drug: Valsartan 4
Normalized name: valsartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 4 mg/kg/day (non-CKD subgroup)
Study: 33262414
Drug: Sublingual fentanyl
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual fentanyl 100 µg
Study: 38528476
Drug: Lasmiditan 100
Normalized name: lasmiditan 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasmiditan 100 mg
Study: 32452181
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (Fengshi spine fixed-point rotation reduction plus routine dehydration and anti-inflammation)
Study: 34916216
Drug: Margetuximab plus
Normalized name: Margetuximab
DrugBank: Margetuximab (DB14967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Margetuximab plus chemotherapy
Study: 35418312
Drug: Margetuximab plus
Normalized name: Margetuximab
DrugBank: Margetuximab (DB14967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Margetuximab plus chemotherapy in CD16A-158F allele carriers
Study: 32870298
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume group (6 mL/kg predicted body weight)
Study: 32870298
Drug: Conventional tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tidal volume group (10 mL/kg predicted body weight)
Study: 34772441
Drug: Oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotic treatment
Study: 34380867
Drug: Single-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose regimen of 4 L PEG (Nulytely) administered a day before the procedure
Study: 32932235
Drug: Flavonoid supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavonoid supplementation (678 mg FLAVs including quercetin, green tea catechins, and bilberry anthocyanins)
Study: 33340297
Drug: Fampridine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fampridine (10 mg, 2 times a day for 24 weeks)
Study: 33340297
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same administration as fampridine)
Study: 33340297
Drug: Fampridine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fampridine (10 mg, 2 times a day for 12 weeks after placebo)
Study: 32006156
Drug: 23-month ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT)
Study: 32006156
Drug: 12-month aspirin
Normalized name: aspirin / menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month aspirin monotherapy following 12-month DAPT
Study: 33971940
Drug: Naoxintong (NXT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naoxintong (NXT) capsule (3 pills, 3 times daily for 12 weeks)
Study: 32814493
Drug: Laxatives only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxatives only (Control Group)
Study: 36657898
Drug: HMB (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB (3 g/day)
Study: 35731653
Drug: Bivalent prefusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent prefusion F (RSVpreF) vaccine
Study: 36384907
Drug: Vibegron 75
Normalized name: vibegron 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibegron 75 mg
Study: 32639468
Drug: Ambrisentan (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan (2.5 mg in suspension, daily for 3 days)
Study: 34066577
Drug: Multi-nutrient fortified
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-nutrient fortified dairy-based drink (400 mL)
Study: 34066577
Drug: Multi-nutrient fortified
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-nutrient fortified dairy-based drink (600 mL)
Study: 36200642
Drug: Reduced-dose PTCy/ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose PTCy/ATG (40 mg/kg/d on days 3 and 4 for PTCy; 2.5 mg/kg on day 8 for ATG)
Study: 35840747
Drug: Standard-dose ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose ATG (10 mg/kg)
Study: 32296931
Drug: Hesperidin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hesperidin (1 g/day)
Study: 32296931
Drug: Flaxseed (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (30 g/day)
Study: 32296931
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of flaxseed and hesperidin (30 g flaxseed and 1 g hesperidin)
Study: 33284796
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no supplement)
Study: 33752423
Drug: Nomogram model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomogram model developed using independent prognostic factors (Grade, T stage, liver surgery, chemotherapy, radiation recode, alpha‐fetoprotein level, fibrosis score, tumor size group, M stage)
Study: 32280089
Drug: Hydromethylthionine 200
Normalized name: Hydromethylthionine mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromethylthionine 200 mg/day
Study: 38082227
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg ketamine
Study: 36114799
Drug: Valbenazine 40-mg
Normalized name: valbenazine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valbenazine 40-mg
Study: 36114799
Drug: Valbenazine 80-mg
Normalized name: valbenazine 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valbenazine 80-mg
Study: 33653802
Drug: Rapamycin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapamycin 0.5 mg
Study: 36145067
Drug: LCHF diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCHF diet (<50 g CHO p/day)
Study: 615901264
Drug: Double placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double placebo (injections and gel)
Study: 37100187
Drug: Atomoxetine 80
Normalized name: atomoxetine 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 80 mg daily
Study: 36477706
Drug: Sugammadex 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 1.0 mg/kg
Study: 32940653
Drug: Timolol thermosensitive
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol thermosensitive gel (0.1%) applied twice daily for 8 weeks
Study: 32940653
Drug: Placebo thermosensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo thermosensitive gel applied twice daily for 8 weeks
Study: 32940653
Drug: Timolol thermosensitive
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol thermosensitive gel (0.1%)
Study: 32940653
Drug: Placebo thermosensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo thermosensitive gel
Study: 32619077
Drug: Ribociclib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib plus endocrine therapy
Study: 32398199
Drug: Double-dose rifampicin
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-dose rifampicin (20 mg/kg/d)
Study: 36055669
Drug: IV TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV TXA 2 g
Study: 32746647
Drug: Lanreotide (LAN)
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanreotide (LAN) and antidiarrhoeal treatments (TAD)
Study: 32746647
Drug: Antidiarrhoeal treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiarrhoeal treatments only (TADS)
Study: 33166718
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg fixed dose)
Study: 38751442
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2)
Study: 32472012
Drug: NOMAC/E2 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOMAC/E2 (2.5 mg nomegestrol acetate and 1.5 mg estradiol)
Study: 32472012
Drug: GS/EE (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS/EE (0.075 mg gestodene and 0.02 mg ethinyl estradiol)